Organization (Other)
PIRAMAL ENTERPRISES LIMITED
ClinicalTrials.gov lists PIRAMAL ENTERPRISES LIMITED as lead sponsor of 23 trials, counting the companies grouped under it. PIRAMAL ENTERPRISES LIMITED itself has 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers PIRAMAL ENTERPRISES LIMITED and 1 company grouped under it: 23 lead-sponsored trials (23 its own, 0 in the grouped companies) and 9 legal-entity registrations (1 its own, 8 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| PIRAMAL PHARMA LIMITED | 0 | 8 |
Disease areas (15)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Head and Neck Neoplasms | 3 |
| Carcinoma, Squamous Cell | 2 |
| Melanoma | 2 |
| Multiple Myeloma | 2 |
| Squamous Cell Carcinoma of Head and Neck | 2 |
Showing 5 of 15 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2014 | 1 |
| 2013 | 3 |
| 2012 | 4 |
| 2011 | 3 |
| 2010 | 1 |
| 2009 | 4 |
| 2008 | 5 |
| 2006 | 1 |
| 2005 | 1 |
Recruitment duration, a model prediction: none of the 23 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| TINEFCON | 1 |
| CISPLATIN | 1 |
| GEMCITABINE | 1 |
| Vemurafenib | 1 |
Journals published in (1)
| Journal | Publications |
|---|---|
| Nature reviews. Cancer | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 66 | 19 | 2025-08-26 |
Manufacturing and distribution sites (5)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Piramal Pharma Limited | Navi Mumbai, IN | EMA, FDA, Health Canada | Piramal (India) |
| Piramal Pharma Limited | Sangareddy, IN | EMA | Piramal (India) |
| Piramal Pharma Limited | Ahmedabad, IN | EMA, FDA | Piramal (India) |
| Piramal Enterprises Limited | Kohir Mandal, Medak Dist., IN | Health Canada | |
| PIRAMAL ENTERPRISES LIMITED | ZAHEERABAD, IN | EMA |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Iqvia Holdings Inc. | Uses vendor | 1 |
Latest dated events (134)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-30 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-03-03 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-02-13 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-11-01 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-08-26 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 134 events.
Biomarker capability evidence (31)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| CD19 | Trial sponsor | Named in trial inclusion criteria |
| CD5 | Trial sponsor | Named in trial inclusion criteria |
| CYP2C9 | Trial sponsor | Named in trial inclusion criteria |
| IL2 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 31 evidence rows.
On Scientist.com
PIRAMAL ENTERPRISES LIMITED is listed as a research supplier in the Scientist.com network.
Service areas
Piramal Healthcare provides custom manufacturing services.
- Website
- piramalhealthcare.com
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Piramal Healthcare on Scientist.com
For prices, more details, or to contact Piramal Healthcare, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.